LICENSE AGREEMENTLicense Agreement • May 9th, 2018 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is executed as of March 5, 2018 (the “Effective Date”) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 3911 Sorrento Valley Blvd #110, San Diego, CA 92121 (“Ligand”) and Roivant Sciences GmbH, a corporation organized under the laws of Switzerland and having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Licensee”). Ligand and Licensee are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
AMENDMENT NO. 5 TO SUBLICENSE AGREEMENTSublicense Agreement • May 9th, 2018 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT (the “Amendment”) is made and entered into as of March 20, 2018 (“Amendment Effective Date”) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, Amendment No. 3 to Sublicense Agreement dated February 27, 2015 and Amendment No. 4 to Sublicense Agreement dated September 17, 2015 (the “Sublicense Agreement”) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 3911 SORRENTO VALLEY BOULEVARD, SUITE 110, SAN DIEGO, CA 92121 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (“PCOP”), a limited liability company organized under the laws of Delaware and having a place of business at 3911 SORRENTO VALLEY BOULEVARD, SUITE 110, SAN D
